Volume 11, Number 8—August 2005
Dispatch
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Ran D. Balicer*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Table A5
Relative risk (RR) and 95% confidence interval (95% CI) for influenza infection and protective efficacy of individual trials with estimate of preexposure (seasonal) prophylaxis
| Trial | Drug | RR (95% CI) | Protective efficacy (%) | p value for heterogeneity |
|---|---|---|---|---|
| Hayden et al. (11) | Oseltamivir | 0.26 (0.13–0.50) | 74 | |
| Monto et al. (15) | Zanamivir | 0.32 (0.17–0.63) | 68 | |
| Overall | 0.29 (0.20–0.43) | 71 | 0.643 |
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.